Azithromycin has relatively broad but shallow antibacterial activity. It appears to be effective in the treatment of chronic obstructive pulmonary disease through its suppression of inflammatory processes and potentially useful in asthma and sinusitis via this mechanism. Azithromycin is believed to produce its effects through suppressing certain immune responses that may contribute to inflammation of the airways. Azithromycin has also shown to inhibit Zika virus and SARS-CoV-2 (the pathogen responsible for COVID-19) growth in vitro.
These simulations are presented to inform researchers and provide a tool for discussing target concentrations in the relevant tissue (lung) over time. Not presented is the variability of target concentration, but between-subject variability in pharmacokinetics was simulated. The simulations have not accounted for differences in protein binding between the in vitro cell culture systems and protein binding in either plasma or lung.
The in silico workbench is intended for use by researchers to assist with clinical trial design and for exploratory and educational purposes. It is NOT intended for use in the diagnosis, cure, mitigation or treatment of any disease. Data provided are not intended to suggest that any product and/or dosing regimen are safe and effective for any use and are for informational purposes only. Please see Terms and Conditions for additional information.